Table of Contents

Mitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling

  1. Jean-Pierre Julien1,2
  1. 1CERVO Brain Research Centre, Québec City, Québec G1J 2G3, Canada
  2. 2Department of Psychiatry and Neuroscience, Université Laval, Québec City, Québec G1V 0A6, Canada
  1. Author contributions: K.D. and J.-P.J. designed research; K.D., S.S.T., H.B., and C.B. performed research; K.D., S.S.T., H.B., C.B., and J.-P.J. analyzed data; K.D. wrote the first draft of the paper; J.-P.J. edited the paper; J.-P.J. wrote the paper.

Abstract

To investigate the role of neuronal NF-κB activity in pathogenesis of amyotrophic lateral sclerosis (ALS), we generated transgenic mice with neuron-specific expression of a super-repressor form of the NF-κB inhibitor (IκBα-SR), which were then crossed with mice of both sexes, expressing ALS-linked gene mutants for TAR DNA-binding protein (TDP-43) and superoxide dismutase 1 (SOD1). Remarkably, neuronal expression of IκBα-SR transgene in mice expressing TDP-43A315T or TDP-43G348C mice led to a decrease in cytoplasmic to nuclear ratio of human TDP-43. The mitigation of TDP-43 neuropathology by IκBα-SR, which is likely due to an induction of autophagy, was associated with amelioration of cognitive and motor deficits as well as reduction of motor neuron loss and gliosis. Neuronal suppression of NF-κB activity in SOD1G93A mice also resulted in neuroprotection with reduction of misfolded SOD1 levels and significant extension of life span. The results suggest that neuronal NF-κB signaling constitutes a novel therapeutic target for ALS disease and related disorders with TDP-43 proteinopathy.

SIGNIFICANCE STATEMENT This study reports that neuron-specific expression of IκB super-repressor mitigated behavioral and pathologic changes in transgenic mouse models of amyotrophic lateral sclerosis expressing mutant forms of either Tar DNA-binding protein 43 or superoxide dismutase. The results suggest that neuronal NF-κB signaling constitutes a novel therapeutic target for amyotrophic lateral sclerosis and related disorders with Tar DNA-binding protein 43 proteinopathy.

  • Received March 6, 2020.
  • Revision received May 12, 2020.
  • Accepted May 18, 2020.

This is an open-access article distributed under the terms of the Creative Commons Attribution License Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Related Article

FREE ACCESS ARTICLE
Responses to This Article
Be the first to respond to this article
Advertisement